News Releases Year: All News20212020201920182017201620152014 Items per page All News2550 Summary ToggleAdditional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program Summary Toggle September 13, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH Summary Toggle September 10, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders Summary Toggle July 23, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved Summary Toggle July 13, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Announces Adjournment of Annual Meeting Summary Toggle June 25, 2021 View News Release > Summary ToggleHepion Pharmaceuticals to be Added to the Russell Microcap® Index Summary Toggle June 9, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH Summary Toggle May 6, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress Summary Toggle April 29, 2021 View News Release > Summary ToggleDIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431 Summary Toggle March 23, 2021 View News Release > Summary ToggleHepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference Summary Toggle March 22, 2021 View News Release > Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
